Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative

Masaichi Abe, Naoki Tsuji, Fumiaki Takahashi, Yusuke Tanigawara

Research output: Contribution to journalReview article

12 Citations (Scopus)


Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position. The clinical development of this product has included a Phase I multiple dose study, early and late Phase II studies, a Phase III study, a clinical pharmacology study to investigate pharmacokinetics in postmenopausal women, a drug interaction study, a bioequivalence formulation study and a clinical pharmacology study to investigate pharmacokinetics in patients with impaired liver function. Using data from all these studies, we sought to characterize the pharmacokinetic profile of eldecalcitol.

Original languageEnglish
Pages (from-to)261-274
Number of pages14
JournalJapanese Pharmacology and Therapeutics
Issue number3
Publication statusPublished - 2011 Mar 1



  • Active vitamin D
  • Edirol
  • Eldecalcitol
  • Osteoporosis
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this